216 related articles for article (PubMed ID: 34497220)
1. [Interleukin-34: a key molecule in the tumor microenvironment].
Kajihara N; Seino KI
Rinsho Ketsueki; 2021; 62(8):1302-1307. PubMed ID: 34497220
[TBL] [Abstract][Full Text] [Related]
2. Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy.
Mortezaee K; Majidpoor J
Cell Oncol (Dordr); 2022 Jun; 45(3):333-353. PubMed ID: 35587857
[TBL] [Abstract][Full Text] [Related]
3. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
[No Abstract] [Full Text] [Related]
4. Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy.
Han ZJ; Li YB; Yang LX; Cheng HJ; Liu X; Chen H
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011369
[TBL] [Abstract][Full Text] [Related]
5. IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment.
Liu K; Huang A; Nie J; Tan J; Xing S; Qu Y; Jiang K
Front Immunol; 2021; 12():683332. PubMed ID: 34093586
[TBL] [Abstract][Full Text] [Related]
6. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
Phuengkham H; Ren L; Shin IW; Lim YT
Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
8. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses.
Brempelis KJ; Cowan CM; Kreuser SA; Labadie KP; Prieskorn BM; Lieberman NAP; Ene CI; Moyes KW; Chinn H; DeGolier KR; Matsumoto LR; Daniel SK; Yokoyama JK; Davis AD; Hoglund VJ; Smythe KS; Balcaitis SD; Jensen MC; Ellenbogen RG; Campbell JS; Pierce RH; Holland EC; Pillarisetty VG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115946
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.
Faraj JA; Al-Athari AJH; Mohie SED; Kadhim IK; Jawad NM; Abbas WJ; Jalil AT
Med Oncol; 2022 Sep; 39(12):239. PubMed ID: 36175691
[TBL] [Abstract][Full Text] [Related]
10. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
Osipov A; Saung MT; Zheng L; Murphy AG
J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
[TBL] [Abstract][Full Text] [Related]
11. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
Sun B; Hyun H; Li LT; Wang AZ
Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
13. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
14. [Immune cell contexture in the tumor microenvironment].
Fujii SI
Rinsho Ketsueki; 2020; 61(9):1424-1432. PubMed ID: 33162545
[TBL] [Abstract][Full Text] [Related]
15. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
[TBL] [Abstract][Full Text] [Related]
17. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticles mediated tumor microenvironment modulation: current advances and applications.
Raju GSR; Pavitra E; Varaprasad GL; Bandaru SS; Nagaraju GP; Farran B; Huh YS; Han YK
J Nanobiotechnology; 2022 Jun; 20(1):274. PubMed ID: 35701781
[TBL] [Abstract][Full Text] [Related]
19. The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy.
Wo YJ; Gan ASP; Lim X; Tay ISY; Lim S; Lim JCT; Yeong JPS
Cells; 2019 Dec; 9(1):. PubMed ID: 31861847
[TBL] [Abstract][Full Text] [Related]
20. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
Balta E; Wabnitz GH; Samstag Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
